Class in Session: DLL3 as a Therapeutic Target in Small-Cell Lung Cancer

Download slides, review a text module, and read an expert commentary on the rationale and clinical development of therapies targeting DLL3 for patients with small-cell lung cancer

Share

Program Content

Activities

DLL3 in SCLC: Module
Class in Session: DLL3 as a Therapeutic Target in Small-Cell Lung Cancer
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: April 12, 2023

Expires: April 11, 2024

Activities

DLL3 in SCLC: Slides
Class in Session: DLL3 as a Therapeutic Target in Small-Cell Lung Cancer
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: April 12, 2023

Activities

DLL3 in SCLC
DLL3: Bringing Bispecific Therapy to SCLC
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: May 11, 2023

Faculty

cover img faculity

Hossein Borghaei, MS, DO

Professor and Chief, Thoracic Medical Oncology
The Gloria and Edmund M. Dunn Chair in Thoracic Oncology
Department of Hematology and Oncology
Fox Chase Cancer Center
Philadelphia, Pennsylvania

cover img faculity

Ticiana Leal, MD

Associate Professor of Medicine
Department of Hematology/Oncology
Director, Thoracic Medical Oncology Program
Winship Cancer Institute
Emory University
Atlanta, Georgia

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

This activity is supported by educational funding provided by

Amgen